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TransplantatABSTRACT
This retrospective study examined the effect of adrenocorticotropic hormone therapy on
remission of recurrent focal segmental glomerulosclerosis (FSGS) in patients with history
of kidney transplant (KT) treated at 2 transplant centers. Patients with biopsy-confirmed
FSGS following KT who received Acthar Gel (Mallinckrodt ARD, Bedminster, New
Jersey, United States) treatment for 1 month were eligible. A total of 14 patients with
idiopathic FSGS were included. Acthar Gel treatment resulted in complete remission of
FSGS in 3 patients and partial remission in 2 patients for a total treatment response rate of
36% (5/14) of patients. Among patients showing complete or partial remission, Acthar Gel
treatment duration ranged from 6 months to 2 years and 60% (3/5 patients) had serum
creatinine  2 mg/dL at the start of Acthar Gel treatment. Patient outcomes suggest
Acthar Gel may be an effective and tolerable treatment for recurrent FSGS in patients with
history of KT. Early initiation of Acthar Gel treatment and therapy duration of at least 6
months may be needed for optimal response to Acthar Gel in patients with history of KT
and recurrent FSGS.Supported by an unrestricted medical writing grant from Mal-
linckrodt ARD, Inc. A medical accuracy review has been provided
by Mallinckrodt Pharmaceuticals only with regard to regulatory
accuracy in discussions of Mallinckrodt products and use of the
Mallinckrodt name.
AS has been a speaker on behalf of Mallinckrodt Pharma-
ceuticals, Inc. MG has nothing to disclose.
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Aurora, CO 80045. Tel: 720-848-2237; Fax: 720-848-2238.
E-mail: Monica.Grafals@ucdenver.eduPATIENTS with history of kidney transplant (KT) whohave proteinuria in the nephrotic range have a high
rate of graft loss, and recurrent nephrotic syndrome (NS) is
a major cause of nephrotic-range proteinuria [1]. Excluding
patients who had death with a functioning graft, out of 1505
patients with biopsy-confirmed glomerulonephritis, NS
recurrence post-KT was the second-leading cause of allo-
graft loss over 10 years, following chronic rejection [2]. In
patients with idiopathic focal segmental glomerulosclerosis
(FSGS), recurrence has been reported in up to 40% of
patients with history of KT, increasing to 80% among pa-
tients with FSGS recurrence in a previous allograft, with
30% to 50% of these patients experiencing loss of their
renal allograft [3,4]. Thus, there is an ongoing need for
effective and tolerable treatments to optimize proteinuria
reduction and graft survival in patients with a KT history
and NS.
Currently, there are no guidelines or standard protocols for
managing proteinuria in patients with recurrent NS following
KT, and therapies such as renin-angiotensin-aldosterone
system blockade, plasmapheresis, and immunosuppressive
or cytotoxic regimens have shown inconsistent results, with
unknown long-term efficacy and tolerability in patients withAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
enue, New York, NY 10169
ion Proceedings, 51, 1831e1837 (2019)KT [5e7]. Acthar Gel is an adrenocorticotropic hormone that
is a US Food and Drug administrationeapproved treatment
to induce diuresis or remission of proteinuria in NS without
uremia of the idiopathic type or in that due to lupus erythe-
matosus. Adrenocorticotropic hormone has shown promise,
with results demonstrating complete or partial remission of
proteinuria in patients with NS of varied etiology in native
kidneys [8e12]. Reports of the use of Acthar Gel in patients
with recurrentNS post-KThave been previously reported in 2
case studies and a case review of patients with recurrent0041-1345/19
https://doi.org/10.1016/j.transproceed.2019.04.052
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Table 1. Patient Demographic and Clinical Characteristics
Patient Age* (y) Sex Race KT Number Donor Pre-KT Diagnosis Post-KT Diagnosis
1 42 M W 1 LU FSGS FSGS
2 32 M L 1 LU FSGS FSGS
3 35 M AA 1 LU FSGS FSGS
4 32 F W 1 LR FSGS FSGS
5 24 M AA 2 D FSGS FSGS
6 59 F AA 1 D FSGS FSGS
7 47 M W 1 D FSGS FSGS
8 46 F AA 1 LU FSGS FSGS
9 49 M AA 1 LU FSGS FSGS
10 68 M W 2 D FSGS FSGS
11 27 M W 2 D FSGS FSGS
12 60 F W 1 LR FSGS FSGS
13 16 M AA 1 LR FSGS† FSGS
14 33 M L 1 D HTN‡ FSGS
Abbreviations: AA, African American; AS, Alport syndrome; D, deceased donor; F, female; FSGS, focal segmental glomerulosclerosis; HTN, hypertension; KT, kidney
transplant; L, Latino; LR, living related donor; LU, living unrelated donor; M, male; NS, nephrotic syndrome; W, White.
*Age at Acthar Gel initiation.
†FSGS diagnosis was not confirmed by biopsy.
‡Patient was presumed to have recurrent FSGS not confirmed by biopsy.
1832 GRAFALS AND SHARFUDDINFSGS, and suggest effective proteinuria reduction [13e15]. In
this retrospective study, we examined Acthar Gel therapy in
patients with KT and posttransplant FSGS. We report the
effect of Acthar Gel therapy on proteinuria and remission of
FSGS, and the tolerability of Acthar Gel therapy in patients
with history of KT.We also report the details of one case that
serves as an illustration of the complexity of treating patients
with KT and posttransplant FSGS.METHODS
Patients at 2 transplant centers with biopsy-confirmed FSGS
following KT who received Acthar Gel treatment for 1 month and
had proteinuria assessed pre- and post-Acthar Gel were included in
this retrospective chart review study. The institutional review board
of the Georgetown-Howard Universities Center for Clinical and
Translational Science and the Indiana University School of Medi-
cine each approved this study. Patients enrolled from the
Georgetown-Howard Universities Center for Clinical and Trans-
lational Science provided informed consent. Formal consent is notTable 2. Patient Treatment Histor
Patient Induction Therapy Treatment Prior to Acthar Gel Ma
1 Alemtuzumab PP, belatacept
2 Alemtuzumab PP, abatacept
3 Alemtuzumab PP, belatacept
4 Alemtuzumab PP, abatacept
5 Alemtuzumab PP
6 Alemtuzumab PP, belatacept
7 Alemtuzumab PP
8 Alemtuzumab No treatment
9 ATG Prednisone
10 ATG No treatment
11 ATG PP, rituximab, prednisone
12 ATG PP, rituximab, prednisone
13 ATG No treatment
14 ATG PP
Abbreviations: ACE-I, angiotensin-converting enzyme-inhibitors; ARB, angiotensin
N, no; PP, plasmapheresis; Y, yes.required by the Indiana University School of Medicine for this type
of study. Patient demographic and clinical characteristics, KT-
related induction and maintenance immunosuppressive therapies,
FSGS treatment history, Acthar Gel dose, Acthar Gel treatment
duration, adverse events (AEs), and allograft outcomes were
collected from medical records. Renal function was evaluated using
serum creatinine (SCr) level, with renal insufficiency defined as SCr
> 1.3 mg/dL. Proteinuria was assessed using urine protein-
creatinine ratio (UPCR; g/g). Complete remission was defined as
final UPCR < 0.50 g/g and SCr  25% increase from pre-Acthar
Gel treatment. Partial remission was defined as 50% reduction
in proteinuria from pre-Acthar Gel treatment, final UPCR 0.50 to
3.50 g/g, and SCr  25% increase from pre-Acthar Gel treatment.
Failure to meet criteria for complete or partial remission was
defined as no response to Acthar Gel treatment. Patient data were
summarized using percentages and descriptive statistics.
RESULTS
Among the 14 patients whomet inclusion criteria, 71%(10/14)
weremale and 43% (6/14) were white (Table 1).Most patientsy Following Kidney Transplant
intenance Treatment at Acthar Gel Start ACE-I/ARB at Acthar Gel Start
MMF, prednisone Y
MMF, abatacept, prednisone Y
MMF, belatacept, prednisone Y
MMF, prednisone N
MMF, tacrolimus N
MMF, tacrolimus N
MMF, tacrolimus, prednisone Y
MMF, tacrolimus Y
MMF, tacrolimus, prednisone Y
MMF, tacrolimus Y
MMF, tacrolimus, prednisone Y
MMF, cyclosporine, prednisone Y
MMF, tacrolimus N
MMF, tacrolimus, prednisone N
II receptor blockers; ATG, antithymocyte globulin; MMF, mycophenolate mofetil;
Table 3. Acthar Gel Treatment Outcome
Patient
Time From KT
to Acthar Gel (d)
Time From FSGS Diagnosis
to Acthar Gel (d)
Acthar Gel
Duration (mo)
eGFR
Pre-Acthar Gel,
Post-Acthar Gel,
% Change (cc/min)
SCr
Pre-Acthar Gel, Post-Acthar
Gel, % Change (mg/dL)
UPCR
Pre-Acthar Gel, Post-Acthar
Gel, % Change (g/g)
Acthar Gel
Treatment Response
Graft Failure (Y/N; mo
From End of Acthar Gel)
1 97 20 6 58, 77, þ32.8 1.46, 1.16, -20.5 7.67, 0.60, -92.2 Partial remission N
2 46 27 20 30, <10, -66.7 2.67, ESRD, NA 38.00, 10.00, -73.7 No response
([SCr > 25%)
Y (0)
3 113 21 6 59, 47, -20.3 1.74, 2.13, þ22.4 3.77, 1.30, -65.5 Partial remission N
4 507 9 6 22, 12, -45.5 2.70, 4.63, þ71.5 2.60, 2.60, 0 No response Y (0)
5 45 22 2 <10, <10, 0 5.24, ESRD, NA 8.83, ESRD, NA No response Y (0)
6 19 7 24 43, 79, þ83.7 1.48, 0.90, -39.2 3.12, 0.30, -90.4 Complete remission N
7 340 311 1 27, <10, -63.0 2.72, ESRD, NA 7.65, 10.00, þ30% No response Y (2)
8 1313 14 1 40, 39, -2.5 1.75, 1.81, þ3.4 2.26, 2.26, 0 No response NA
9 1602 122 2 25.7, 19.2, -25.3 3.80, 5.10, þ34.2 5.70, 2.56, -55.1 No response
([SCr > 25%)
Y (29)
10 1178 239 6 27, 40, þ48.1 2.40, 1.99, -17.1 3.90, 3.06, -21.5 No response N
11 1120 1048 7 56.1, 49.4, -11.9 1.12, 1.27, þ13.4 4.64, 7.73, þ66.6 No response N
12 325 310 20 32, 30, -6.3 1.63, 1.73, þ6.1 6.90, 6.57, -4.8 No response Y (38)
13 0* 0* 6 18, 54, þ200.0 3.49, 1.40, -59.9 3.50, 0.30, -91.4 Complete remission N
14 14 5 6 37, 51, þ37.8 2.08, 1.57, -24.5 3.3, 0.4, -87.9 Complete remission N
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; KT, kidney transplant; N, no; NA, not available; SCr, serum creatinine; UPCR,
urinary protein-creatinine ratio; Y, yes.
*Patient began Acthar Gel therapy prior to KT.
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Fig 1. Effect of Acthar Gel treatment on serum creatinine (SCr),
estimated glomerular filtration rate (eGFR) and urine protein-
creatinine ratio (UPCR) in (A) patients showing partial or com-
plete recovery (n ¼ 5), and (B) patients showing no recovery
(n ¼ 9*). *Not all patients had values at the finish of Acthar Gel
therapy. For SCr, n ¼ 6; for eGFR, n ¼ 9; for UPCR, n ¼ 8.
Only patients with values at both the start and finish of Acthar
Gel therapy are represented above in Fig 1.
Fig 2. Individual changes in urine protein-creatinine ratio
(UPCR, g/g) over the course of Acthar Gel therapy.* *Case 5
was in end-stage renal disease at the termination of Acthar Gel
therapy and, therefore, unable to provide posteActhar Gel
UPCR values.
1834 GRAFALS AND SHARFUDDIN(79% [11/14]) underwent KT for the first time and 21% (3/14)
had received a second transplant. Patients received kidneys
from deceased donors (43% [6/14]), living unrelated donors
(36%[5/14]), and living relateddonors (21%[3/14]).Mean age
post-KT  SD, at the start of Acthar Gel therapy, was 40.7 
14.9 years old (range, 16-68 years).
Induction immunotherapy included alemtuzumab (57%
[8/14] of patients) and antithymocyte globulin (43% [6/14]).
Ongoing maintenance immunosuppression (Table 2)
included mycophenolate mofetil for all patients, tacrolimus
for 64% (9/14) of patients, prednisone for 64% (9/14), and
one patient each with abatacept, belatacept, and cyclo-
sporine. Additionally, 64% (9/14) of patients received
ongoing treatment with an angiotensin-converting enzyme-
inhibitor (ACE-I) or angiotensin II receptor blocker. FSGS
treatment prior to initiation of Acthar Gel (Table 2) included
plasmapheresis (71% [10/14] of patients), high-dose predni-
sone (21% [3/14]), abatacept (14% [2/14]), belatacept (21%
[3/14]), and rituximab (14% [2/14]), whereas 21% (3/14) of
patients received no prior FSGS treatment except for stan-
dard center-based post-KT immunosuppression.
Time to initiation of Acthar Gel following KT varied across
patients (Table 3), including 1 patient who began Acthar Gel
therapy prior to KT (pediatric patient), 2 patients who beganActharGel 14 to 20 days followingKT, another 4 patients who
began Acthar Gel 21 to 113 days following KT, and 7 patients
who initiated Acthar Gel from 325 days to 1602 days following
KT. Excluding the patient who began Acthar Gel prior to KT,
the time from FSGS diagnosis following KT to Acthar Gel
initiation ranged from 5 to 1048 days. All patients received
Acthar Gel 80 units twice per week. Duration of Acthar Gel
treatment ranged from 1 to 24 months (median ¼ 6.0) with
71% (10/14) of patients receivingActharGel treatment for6
months.
Proteinuria reduction following Acthar Gel treatment
resulted in complete remission in 3 patients and partial
remission in 2 patients for a total treatment response rate of
36% (5/14) of patients (Table 3). Among patients showing
complete or partial remission, Acthar Gel treatment dura-
tion ranged from 6 months to 2 years and 60% (3/5 patients)
had SCr  2 mg/dL at the start of Acthar Gel. Two patients
(patients 2 and 9) showed large reductions in proteinuria
(55% and 74%) but did not meet remission criteria due to
SCr worsening >25%. Among the remaining 7 patients
showing no response, Acthar Gel treatment duration
was <6 months in 43% (3/7) of patients, 2 of whom dis-
continued treatment due to kidney failure. Among all 9
nonresponders, 67% (6/9) had SCr  2.4 mg/dL at treat-
ment initiation. Overall, in those patients with available
values, estimated glomerular filtration rate tended to be
higher in patients with either a partial or complete response
and increased over continued duration of Acthar Gel
treatment (Fig 1). Patients showing no response tended to
have lower estimated glomerular filtration, which declined
further during Acthar Gel treatment. During Acthar Gel
treatment, SCr tended to decline in patients demonstrating
a response but increased in those who did not respond
(Fig 1). UPCR tended to decrease, on average, in all pa-
tients over the course of Acthar Gel treatment but declined
to a substantially greater degree in those patients who
Fig 3. Renal biopsy approximately
1 month following transplant and
prior to Acthar Gel therapy in a pa-
tient with recurrent focal segmental
glomerulosclerosis (FSGS). (A) He-
matoxylin and eosin (H & E) stain;
(B) Trichrome stain; (C) Electron mi-
croscopy; (D) Electron microscopy.
ADRENOCORTICOTROPIC HORMONE FOLLOWING KT 1835showed a partial or complete response compared to those
who did not respond (Fig 1, Fig 2).
Over the studyperiod, graft failure occurred in 43%(6/14) of
patients. AEs were reported by 29% (4/14) of patients during
Acthar Gel therapy, including swelling or edema (2/14), tired-
ness or fatigue (1/14), diabetes (1/14), hyperglycemia (1/14),
and weight gain (1/14). No patient discontinued Acthar Gel
treatment due to AEs.Fig 4. Renal biopsy in a patient
with recurrent focal segmental glo-
merulosclerosis (FSGS). Upper
panel: At the time of acute renal fail-
ure (consistent with a 1a rejection)
following 6 months of Acthar Gel
therapy. ([A] Hematoxylin and eosin
[H & E] stain; [B] H & E stain.) Lower
panel: Four months after acute
renal failure. ([C] H & E stain; [D]
H & E stain; [E] Electron micro-
scopy; [F] Electron microscopy.)The complexities of treating recurrent FSGS post-KT are
illustrated by patient 1, a white male who was 26 years old
when first diagnosed with FSGS and 42 years old at the time
of post-KT treatment with Acthar Gel. He had been briefly
treated with prednisone and was receiving an ACE-I at the
time of his pre-KT evaluation. He received the transplant,
his first, from a living unrelated donor. Prior to KT, his
proteinuria level was 27 g/day, which decreased to 2 g/day
1836 GRAFALS AND SHARFUDDINimmediately following KT, followed by an increase to 3 g/
day in the first month following KT. Biopsy was delayed 1
month due to the patient’s development of atrial fibrillation
post-KT and treatment with anticoagulation for 1 month.
Biopsy at 1 month post-KT showed recurrent FSGS (Fig 3).
Approximately 2 months post-KT, he was started on bela-
tacept, oral prednisone, lisinopril, and plasmapheresis 3
times per week for 2 months. At 3 months’ post-KT, he
started Acthar Gel 80 units twice per week and following 4
weeks of Acthar Gel therapy, he was successfully weaned
from plasmapheresis. Following 6 months of Acthar Gel
treatment, his UPCR decreased from 7.67 to 0.60 g/g, with
SCr improving from 1.46 to 1.16 mg/dL. He met criteria for
partial remission and Acthar Gel treatment was dis-
continued. At this time, he developed BK-virus viremia and
his post-KT maintenance treatment with mycophenolate
mofetil was decreased. He showed acute renal failure
approximately 1 month later (Fig 4, upper panel), confirmed
4 months later (Fig 4, lower panel); however, he did not
have graft failure.DISCUSSION
Our report of Acthar Gel therapy for FSGS following KT
suggests that Acthar Gel may be an effective and tolerable
treatment for proteinuria reduction in patients with a his-
tory of KT and recurrent NS. Acthar Gel therapy was well
tolerated by patients, with side effects similar to previous
reports [8e12,14,15], and no patient required discontinua-
tion of therapy due to side effects. Patients who had com-
plete or partial remission of proteinuria were more likely
than patients with no response to have lower SCr, indicating
better renal function at initiation of Acthar Gel therapy,
supporting perhaps the importance of early treatment to
optimize proteinuria reduction in response to therapy.
Additionally, the duration of Acthar Gel therapy in all 5
patients who showed complete or partial remission was 6 or
more months. Acthar Gel was used as the initial therapy
directed at FSGS post-KT in 3 patients. Of these patients, 1
showed complete remission and 1 had only received 1
month of ongoing Acthar Gel therapy at the time of the
study. The patient with complete remission was a pediatric
patient with recurrent FSGS who began Acthar Gel therapy
prior to KT. Altogether, our findings suggest earlier onset of
Acthar Gel treatment combined with therapy duration of at
least 6 months may be needed for optimal response to
Acthar Gel post-KT. In many of our patients, Acthar Gel
was used as a “last resort,” and the delay in initiation of
Acthar Gel following FSGS recurrence may have under-
estimated its effectiveness in proteinuria reduction and
support of graft survival.
Two previously reported cases have supported Acthar
Gel effectiveness in recurrent FSGS following KT [13,14].
In both, patients with poor response to plasmapheresis and
rituximab demonstrated significant proteinuria reduction
following Acthar Gel therapy, and in one report, the patient
achieved complete remission. In a recent retrospectivereview of similar cases (n ¼ 20), patients showed significant
improvement of UPCR after receiving Acthar Gel, and 50%
achieved complete or partial remission [16]. It should be
noted, however, that the Alhamad 2019 definitions [16]
establish a lower threshold for partial remission (posttreat-
ment proteinuria of 1-3.5 g/g, increase in creatinine <30%)
and complete remission (posttreatment proteinuria 1 g/g,
increase in creatinine <30%) than the definitions used in
our study. Applying the Alhamad 2019 remission criteria to
our patients would have resulted in 7/14 (50%) achieving
complete or partial remission, equivalent to the finding in
that study. Our patient outcomes of complete or partial
remission in response to Acthar Gel therapy are consistent
with other previous reports of the success of Acthar Gel
treatment in recurrent FSGS, which defined remission
thresholds similar to the ones used by us [8,10e12].
Although our success rate is not as dramatic as those
previously reported, it should be kept in mind that these
patients were already on existing dual or triple immuno-
suppressive drugs for prevention of graft rejection and the
majority were on ACE/angiotensin II receptor blocker
therapies. Most native kidney NS treatment protocols do
not include combination immunosuppressive or other anti-
proteinuric therapies. Many immunosuppressive therapies
such as mycophenolate or calcineurin inhibitors are quite
often used in NS cases. The fact that these patients had
FSGS while on this combination of agents suggests that
these are high-risk patients with a likely high risk for graft
failure. We observed that some cases with FSGS on con-
ventional immunosuppressive agents responded to Acthar
Gel, which suggests that the mechanism of action and
pathogenesis of NS needs further investigation. Lastly, we
find it an encouraging result that there were no other severe
cases of infection noted while on concomitant Acthar Gel
and immunosuppressive drugs.
The specific mechanisms of action by which Acthar Gel
reduces proteinuria are not yet identified. Acthar Gel may
have immunosuppressive and antiinflammatory effects and
may have a direct podocyte-sparing effect in the glomerulus,
possibly related to, but not limited to, activation of the
melanocortin 1 receptor [17e23]. Patients with recurrent
FSGS post-KT have shown diffuse podocyte foot process
effacement, and the extent of effacement was associated
with degree of proteinuria, implicating an important role of
podocyte injury in recurrence [24]. Although the importance
of podocyte injury is considered central to the disease
pathogenesis of recurrent FSGS [22], the circulating factor
responsible for podocyte injury, cytoskeleton reorganiza-
tion, foot process effacement, proteinuria, and podocyte
loss has yet to be identified [6,25].
Our retrospective study provides much needed clinical
practice outcomes in the use of Acthar Gel therapy in pa-
tients with history of KT and FSGS following transplant.
Limitations include the retrospective design, small number
of patients, and lack of standardized study protocols for
Acthar Gel and concurrent therapies. Additionally, there
was no assessment of potential circulating biomarkers in our
ADRENOCORTICOTROPIC HORMONE FOLLOWING KT 1837patients. Our findings suggest further investigation of
Acthar Gel in a prospective trial with larger patient groups,
standardized protocols, and earlier treatment following NS
recurrence is warranted. An important goal is the identifi-
cation of patients who are most likely to benefit from Acthar
Gel’s treatment of recurrent NS following KT.
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